NCT05685277 - Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

February 22, 2023

Study Completion Date

July 31, 2023

Conditions

Bioequivalence

Interventions

DRUG

Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg

Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.

DRUG

Tritace® Plus tablet 10 mg/25 mg

Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.

Trial Locations (1)

Unknown

"Separate medical division Comed (Ligand Research LLC)", Moscow